NDA 021779 · Actelion
Ventavis
Iloprost · Inhalation
NovelPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Mar 2, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Dec 29, 2004
Approved uses
2
Original approval plus efficacy supplements
Registered trials
80
19 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 24, 2005 Supplement 1 · Efficacy LabelLetter
- Dec 29, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
3 products under this application
- VENTAVIS · ILOPROST 10MCG/ML (10MCG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INHALATION · Discontinued
- VENTAVIS · ILOPROST 20MCG/ML (20MCG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INHALATION · Discontinued
- VENTAVIS · ILOPROST 20MCG/2ML (10MCG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INHALATION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Iloprost" as an intervention, any sponsor and status, largest first.
- Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory FailurePivotal-lookingRecruiting
Pär JohanssonAcademic, hospital or other
NCT06319274 · 450 participants (planned) · Start Apr 15, 2024 · Primary completion Sep 30, 2027
Drug: Iloprost; Isotonic saline · For: Acute Respiratory Failure; Endothelial Dysfunction; Pulmonary Infection
Sites: Copenhagen, Denmark; Herlev, Denmark; Hillerød, Denmark · 5 sites in all
- Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ FailurePivotal-lookingCompleted
Jakob Stensballe, MD, PhDAcademic, hospital or other
NCT04123444 · 279 participants · Start Oct 30, 2019 · Primary completion Jun 28, 2022
Drug: Iloprost; Isotonic saline · For: Septic Shock
Sites: Copenhagen, Denmark; Herlev, Denmark; Hillerød, Denmark · 6 sites in all
- Iloprost in High Risk Cardiac Surgical PatientsPivotal-lookingCompleted
Ludwig-Maximilians - University of MunichAcademic, hospital or other
NCT00927654 · 253 participants · Start Jun 2009 · Primary completion Mar 2012
Drug: Iloprost (Ventavis); Isotonic Sodium Chloride solution 0.9 % (placebo) · For: Pulmonary Hypertension
Sites: Aachen, Germany; Bad Oeynhausen, Germany; Berlin, Germany · 6 sites in all
- ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO)Pivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT03788837 · 240 participants · Start Jul 3, 2019 · Primary completion Jan 5, 2024
Drug: ILOPROST; NaCl · For: Septic Shock Hyperdynamic
Sites: Paris, France
- Infusion of Prostacyclin vs Placebo for 72-hours in Trauma Patients With Haemorrhagic Shock Suffering From Organ FailurePivotal-lookingCompleted
Pär JohanssonAcademic, hospital or other
NCT03903939 · 228 participants · Start May 22, 2019 · Primary completion Nov 14, 2021
Drug: Iloprost; Isotonic saline · For: Multi Organ Failure
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 5 sites in all
- Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or InterventionPivotal-lookingCompleted
Onassis Cardiac Surgery CentreAcademic, hospital or other
NCT00345501 · 208 participants · Start Nov 2005
Drug: Iloprost; Placebo · For: Renal Insufficiency, Chronic; Coronary Angiography; Angioplasty, Transluminal, Percutaneous Coronary
Sites: Athens, Greece
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic SclerosisPivotal-lookingCompleted
National Center for Research Resources (NCRR)NIH
NCT00004786 · 200 participants · Start Dec 1995
Drug: iloprost · For: Systemic Sclerosis; Raynaud Disease
- Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)Pivotal-lookingCompleted
Civi Biopharma, Inc.Industry
NCT04040322 · 198 participants · Start Oct 14, 2019 · Primary completion Jun 9, 2021
Drug: Placebo IV infusion; Iloprost Injection, for intravenous use · For: Raynaud's Phenomenon Secondary to Systemic Sclerosis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 30 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Ventavis (Iloprost Tromethamine) · HCPCS Q4074
2024 spending
$641K
Beneficiaries
n/a
30 claims
Per beneficiary
n/a
2024 ASP limit $147.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,203,733 |
| 2021 | $8,709,124 |
| 2022 | $5,644,563 |
| 2023 | $3,536,416 |
| 2024 | $641,135 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Interventions for frostbite injuries.
Lorentzen AK, Davis C, Penninga L · Cochrane Database Syst Rev 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacological treatment for Buerger's disease.
Cacione DG, Macedo CR, do Carmo Novaes F, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Prostacyclin for pulmonary hypertension.
Paramothayan NS, Lasserson TJ, Wells AU, et al. · Cochrane Database Syst Rev 2003 · Systematic Review
- Exercise for intermittent claudication.
Watson L, Ellis B, Leng GC · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
- Pharmacological treatment for Buerger's disease.
Cacione DG, Baptista-Silva JC, Macedo CR · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological treatment for Buerger's disease.
Cacione DG, Macedo CR, Baptista-Silva JC · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.